FleuryBSP:FLRY3 +1.04%91 Days Payable is 43.86 as of Mar. 2026, which is 17% above its 10-year median of 37.61. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Fleury ranks worse than 70.53% on this metric.
Fleury's average Accounts Payable for the
three
months ended in Mar. 2026 was R$767 Mil. Fleury's Cost of Goods Sold for the
three
months ended in Mar. 2026 was R$1,595 Mil.
Hence, Fleury's Days Payable for the
three
months ended in Mar. 2026 was 43.86.
The historical rank and industry rank for Fleury's Days Payable or its related term are showing as below:
BSP:FLRY3'
s Days Payable Range Over the Past 10 Years
Min: 30.22 Med: 37.61 Max: 45.11
Current: 41.93
During the past 13 years, Fleury's highest Days Payable was 45.11. The lowest was 30.22. And the median was 37.61.
BSP:FLRY3's Days Payable is ranked worse than 70.53% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs BSP:FLRY3: 41.93
Fleury's Days Payable
increased
from Mar. 2025 (43.59) to Mar. 2026 (43.86).
It may suggest that Fleurydelayed paying its suppliers.
Fleury Days Payable Related Terms
Fleury Days Payable Historical Data
* Premium members only.
The historical data trend for Fleury's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Fleury's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's Days Payable distribution charts can be found below:
* The bar in red indicates where Fleury's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fleury's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a Days Payable of 43.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fleury and its competitors. This is 17% above median its historical median of 37.61. Over the past decade, Fleury's Days Payable has ranged from 30.22 to 45.11. According to the industry distribution chart, Fleury ranks #134 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 70.5%.
Is Fleury's Days Payable too high?
Fleury's current Days Payable of 43.86 is 17% above median its 10-year median of 37.61. Over the past 10 years, this metric has ranged from a low of 30.22 to a high of 45.11. The Medical Diagnostics & Research industry median Days Payable is 67.28. Fleury's value of 43.86 is 34.8% below this industry median. Based on the distribution chart, Fleury ranks #134 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #134 out of 190 companies for Days Payable. This places Fleury in the lower half of its industry. The industry median Days Payable is 67.28. Fleury's value of 43.86 is 34.8% below this benchmark. Historically, Fleury's own Days Payable has ranged from 30.22 to 45.11 over the past decade. While the company's 10-year median is 37.61 vs. the industry median of 67.28, Fleury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current Days Payable of 43.86 is 34.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current Days Payable is 43.86, which is 17% above median its own 10-year median of 37.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.61 — trading 10.3% below its estimated fair value. The current Days Payable is 43.86, which is 17% above median its 10-year median of 37.61 and 34.8% below the Medical Diagnostics & Research industry median of 67.28. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current Days Payable is 43.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$15.61 is trading 10.3% below its estimated GF Value™ of R$17.41.
GuruFocus considers Fleury to be Modestly Undervalued.
Key valuation signals for BSP:FLRY3:
Days Payable: 43.86 (17% above median its 10-year median of 37.61)
GF Value™: R$17.41 vs. price of R$15.61 (10.3% below fair value)
Industry Position: 34.8% below the Medical Diagnostics & Research median (#134 of 190)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score
Get the complete analysis for BSP:FLRY3
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
